Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunesis Pharmaceuticals has earned a preclinical milestone payment from Johnson & Johnson Pharmaceutical Research & Development or J&JPRD under the companies's drug discovery collaboration agreement.
Subscribe to our email newsletter
The recent milestone payment was triggered by J&JPRD’s selection of a compound targeting the Cathepsin S enzyme as a development candidate. Under the terms of the collaboration agreement, Sunesis has the potential to receive additional development milestone payments from J&JPRD, as well as royalty payments based on future product sales.
Bob McDowell, vice president of research of Sunesis, said: “We believe that a small molecule inhibitor of Cathepsin S will provide a useful approach to treating certain inflammatory conditions and we are pleased by J&JPRD’s advancement of a compound from our collaboration into development.”